Biogen (NASDAQ:BIIB) Stock Sale Revealed by Rep. Maria Elvira Salazar

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on October 7th, the Representative disclosed that they had sold between $1,001 and $15,000 in Biogen stock on September 24th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Citigroup (NYSE:C) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of GE Aerospace (NYSE:GE) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of RH (NYSE:RH) on 9/24/2026.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 9/24/2026.

Biogen Trading Down 1.7%

Shares of BIIB stock opened at $218.43 on Friday. Biogen Inc. has a 1-year low of $138.00 and a 1-year high of $230.49. The firm’s 50-day simple moving average is $216.95 and its 200-day simple moving average is $202.10. The firm has a market cap of $32.27 billion, a P/E ratio of 38.66, a PEG ratio of 2.45 and a beta of 0.09. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same quarter last year, the firm earned $5.47 earnings per share. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities analysts forecast that Biogen Inc. will post 12.41 EPS for the current year.

Hedge Funds Weigh In On Biogen

Institutional investors have recently modified their holdings of the company. Polaris Financial Partners bought a new stake in Biogen during the third quarter valued at about $109,000. Boltwood Capital Management boosted its position in shares of Biogen by 33.1% in the third quarter. Boltwood Capital Management now owns 1,982 shares of the biotechnology company’s stock valued at $448,000 after acquiring an additional 493 shares during the period. QRG Capital Management Inc. grew its stake in shares of Biogen by 47.9% in the second quarter. QRG Capital Management Inc. now owns 48,819 shares of the biotechnology company’s stock worth $10,548,000 after acquiring an additional 15,817 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its stake in Biogen by 20.5% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 1,738 shares of the biotechnology company’s stock valued at $376,000 after purchasing an additional 296 shares during the last quarter. Finally, Tidal Investments LLC increased its holdings in shares of Biogen by 9.0% during the 2nd quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company’s stock worth $13,794,000 after purchasing an additional 5,256 shares during the period. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Citigroup upped their price target on Biogen from $200.00 to $215.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Needham & Company LLC boosted their price objective on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Canaccord Genuity Group raised their target price on shares of Biogen from $245.00 to $248.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Barclays upped their target price on Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $230.00.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.